Compared with other ablative therapies, stereotactic body radiotherapy might offer a ‘particularly advantageous option’ for ...
Renal cell carcinoma highlights from ASCO GU 2025 include follow-up data from the CheckMate 9ER study, updated COSMIC-313 results, and promising early data on casdatifan, a new HIF-2 alpha inhibitor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback